secwatch.observer — SEC 8-K summary
======================================

Issuer:     Denali Therapeutics Inc. (DNLI)
CIK:        0001714899
Form:       8-K
Filed at:   2025-12-10T23:59:59+00:00
Accession:  0001628280-25-056363
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali prices $200M public offering of common stock and pre-funded warrants
---------------------------------------------------------------------------

- Prices 9.14M shares at $17.50 and 2.29M pre-funded warrants at $17.49, raising ~$200M gross proceeds.
- Underwriters granted 30-day option for additional 1.71M shares, potential total $230M gross proceeds.
- Offering expected to close Dec 11, 2025; Goldman Sachs, J.P. Morgan, Morgan Stanley, Jefferies as joint book-runners.
- Pre-funded warrants have $0.01 exercise price, immediately exercisable, with 4.99% beneficial ownership limitation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1714899/000162828025056363/0001628280-25-056363-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1714899/000162828025056363/dnli-20251209.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-056363

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer